Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: efficacy, safety and tolerability …
M Ohtsuki, Y Okubo, M Komine… - The Journal of …, 2017 - Wiley Online Library
Apremilast, an oral, small‐molecule phosphodiesterase 4 inhibitor, works intracellularly
within immune cells to regulate inflammatory mediators. This phase 2b randomized, placebo …
within immune cells to regulate inflammatory mediators. This phase 2b randomized, placebo …
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized …
C Paul, J Cather, M Gooderham… - British Journal of …, 2015 - academic.oup.com
Background Apremilast, an oral phosphodiesterase 4 inhibitor, regulates immune responses
associated with psoriasis. Objectives ESTEEM 2 evaluated the efficacy and safety of …
associated with psoriasis. Objectives ESTEEM 2 evaluated the efficacy and safety of …
[HTML][HTML] Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled …
K Papp, K Reich, CL Leonardi, L Kircik… - Journal of the American …, 2015 - Elsevier
Background Apremilast works intracellularly to regulate inflammatory mediators. Objective
ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to …
ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to …
Real‐world use of apremilast for patients with psoriasis in Japan
M Kishimoto, M Komine, T Hioki… - The Journal of …, 2018 - Wiley Online Library
Apremilast is a novel oral phosphodiesterase 4 inhibitor effective for psoriasis. It regulates
the production of pro‐inflammatory mediators. Apremilast was approved in December 2016 …
the production of pro‐inflammatory mediators. Apremilast was approved in December 2016 …
[HTML][HTML] Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase …
R Bissonnette, DM Pariser, NR Wasel… - Journal of the American …, 2016 - Elsevier
Background Difficult-to-treat palmoplantar psoriasis has a disproportionately negative
impact on quality of life. Objective We evaluated the efficacy and safety of apremilast in …
impact on quality of life. Objective We evaluated the efficacy and safety of apremilast in …
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
AB Gottlieb, RT Matheson, A Menter… - Journal of drugs in …, 2013 - europepmc.org
Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro-inflammatory and anti-inflammatory mediators. This phase II …
intracellularly to modulate pro-inflammatory and anti-inflammatory mediators. This phase II …
Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double‐blind, placebo …
Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro‐inflammatory and anti‐inflammatory mediator production …
intracellularly to modulate pro‐inflammatory and anti‐inflammatory mediator production …
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
Background Apremilast, a small-molecule inhibitor of phosphodiesterase 4, works
intracellularly to modulate proinflammatory and anti-inflammatory mediator production, and …
intracellularly to modulate proinflammatory and anti-inflammatory mediator production, and …
An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast
AB Gottlieb, B Strober, JG Krueger… - … medical research and …, 2008 - Taylor & Francis
Objective: To evaluate the clinical and biological activity of apremilast in patients with severe
plaque-type psoriasis. Research design and methods: Apremilast, a phosphodiesterase‑4 …
plaque-type psoriasis. Research design and methods: Apremilast, a phosphodiesterase‑4 …
Real-world experience with apremilast in treating psoriasis
JN Mayba, MJ Gooderham - Journal of cutaneous medicine …, 2017 - journals.sagepub.com
Background: Clinical trial data have shown apremilast, an oral phosphodiesterase-4
inhibitor, to be efficacious and safe for the treatment of psoriasis. However, little real-world …
inhibitor, to be efficacious and safe for the treatment of psoriasis. However, little real-world …
相关搜索
- plaque psoriasis safety of apremilast
- plaque psoriasis oral phosphodiesterase
- psoriasis in japan apremilast for patients
- safety of apremilast oral phosphodiesterase
- efficacy of apremilast severe psoriasis
- japanese patients oral phosphodiesterase
- plaque psoriasis placebo in patients
- safety of apremilast phase iiib
- safety of apremilast placebo in patients
- plaque psoriasis phase iiib
- efficacy and safety apremilast in subjects
- placebo in patients phase iiib
- safety of apremilast dose comparison
- safety of apremilast parallel group
- plaque psoriasis dose comparison
- plaque psoriasis parallel group